We report an anti‐rheumatic/inflammatory activity of the non‐toxic, tellurium‐based immunomodulatory compound AS101 in experimental RA by reducing disease progression, by blocking extravasation of inflammatory VLA4+ cells into the joint and by preservation of joint tissue architecture.